#Japan #Tokyo #Lecanemab #Eisai #Alzheimer

Eisai to Present New Findings on Alzheimer’s Disease at CTAD 2026

Eisai Co., Ltd. has recently disclosed its plans to present significant new research on Alzheimer's disease (AD) at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference. This important event is scheduled to take place from November 16-19, 2026, in Boston and online, allowing for a broader audience to engage with the latest developments in AD research.

Key Highlights from Eisai’s Presentation

Eisai will showcase compelling findings related to lecanemab (marketed as LEQEMBI®), an anti-amyloid beta (Aβ) protofibril antibody designed for the treatment of Alzheimer’s disease. The data to be presented includes:

• - Results from Five-Year Clarity AD Study: Long-term outcomes from the Clarity AD study will be detailed, focusing on the efficacy of lecanemab after five years of treatment. This includes both core data and long-term extension phases, making it one of the most extensive follow-up studies available for an approved anti-amyloid therapy.

• - LEADER Study Insights: The new analyses from the LEADER study will also be highlighted. This multicenter, real-world, retrospective study examines how lecanemab is utilized in early Alzheimer’s treatment across a range of clinical settings in the United States, three years post-FDA approval.

• - Focus on Safety and Co-Pathology: The presentations seek to address safety profiles, as well as explore α-synuclein co-pathology linked to Alzheimer’s disease as observed in cerebrospinal fluid studies.

Through its scientific program at CTAD 2026, Eisai emphasizes the importance of collaboration and innovation in the field of Alzheimer’s research, providing insights into patient needs and treatment outcomes. Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer of Eisai, stated that the presentations will underline their commitment to enhancing understanding in Alzheimer's care,

Presentation Schedule

Eisai will host a dedicated symposium focusing primarily on LEADER findings, complemented by five oral presentations and 19 poster submissions throughout the conference.

Oral Presentation Highlights Include:

1. Long-Term Outcomes with Lecanemab: Findings from the Clarity AD study through 60 months post-treatment initiation will be shared, covering significant health outcomes for early Alzheimer patients.
2. Real-World Utilization of Lecanemab: A comprehensive meta-analysis regarding safety profiles and adverse event rates in diverse clinical practices will be presented.
3. Lecanemab and α-Synuclein Co-Pathology: New insights from the Clarity AD CSF substudy examining the connections between lecanemab treatment and other pathological processes.

Eisai’s commitment to understanding Alzheimer’s disease is reflected in these presentations, pushing the boundaries of what is known in the diagnosis and treatment of this debilitating condition.

Additional Research Outcomes

Eisai’s poster presentations will delve into various aspects of lecanemab treatment, including:

• - Effectiveness and safety data in real-world contexts
• - Investigations into treatment persistence and the shift to subcutaneous administration
• - Long-term treatment outcomes concerning the biological processes linked to Alzheimer's

Mr. Kramer emphasized that the insights gained from this research not only further the scientific community's understanding of Alzheimer’s disease but also aim to provide essential, actionable knowledge for clinicians and caregivers alike.

The extensive research presented at CTAD 2026 encapsulates the ongoing efforts by Eisai to better the lives of patients suffering from Alzheimer’s, reinforcing its role as a leader in Alzheimer's therapy development and a vital resource in advancing treatment options.

Conclusion

As the CTAD Conference invites a global audience to explore innovative research in Alzheimer's disease, Eisai stands out by combining extensive data with real-world applicability, underlining its long-standing dedication to patients and their families battling this challenging illness.